Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 11/20 | 0.47 |
| ▸ | PGR | P06401 | 4/20 | 0.47 |
| ▸ | AR | P10275 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 2/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13600503 | 1.00 | NR3C1 (0.47) | NR3C1PGRARGAAPOLB | |
| SCHEMBL4437846 | 1.00 | NR3C1 (0.47) | NR3C1PGRARGAAPOLB | |
| SCHEMBL4433787 | 0.94 | NR3C1 (0.49) | NR3C1PGRARGAAPOLB | |
| SCHEMBL4433786 | 0.94 | NR3C1 (0.49) | NR3C1PGRARGAAPOLB | |
| SCHEMBL13607452 | 0.94 | NR3C1 (0.49) | NR3C1PGRARGAAPOLB | |
| SCHEMBL4426524 | 0.92 | NR3C1 (0.47) | NR3C1PGRARGAAPOLB | |
| SCHEMBL4426529 | 0.92 | NR3C1 (0.47) | NR3C1PGRARGAAPOLB | |
| SCHEMBL13600540 | 0.92 | NR3C1 (0.47) | NR3C1PGRARGAAPOLB | |
| SCHEMBL4437790 | 0.91 | NR3C1 (0.52) | NR3C1PGRARGAAPOLB | |
| SCHEMBL4437788 | 0.91 | NR3C1 (0.52) | NR3C1PGRARGAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325961-A1 | INDANE MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-31 | — | — | US | claimed |
| US-7592461-B2 | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-22 | — | — | US | claimed |
| US-20070185056-A1 | Indane modulators of glucocorticoid receptor, AP-1, and/or NF/kB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-09 | — | — | US | claimed |
| US-8324401-B2 | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| US-20090325961-A1 | INDANE MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-31 | — | — | US | disclosed |
| US-7592461-B2 | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-22 | — | — | US | disclosed |
| US-20070185056-A1 | Indane modulators of glucocorticoid receptor, AP-1, and/or NF/kB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325961-A1 | INDANE MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFKB1, NR3C1, NR5A1 | NR3C1 2/4885PGR 640/4885AR 180/4885 |
| US-20070185056-A1 | Indane modulators of glucocorticoid receptor, AP-1, and/or NF/kB activity and use thereof | NFKB1, NR3C1, NR5A1 | NR3C1 2/4885PGR 636/4885AR 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.